SCHEMBL13625138

SCHEMBL13625138

CC(C)Oc1c(-c2ccccc2C=O)cc(Cl)c2cccnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.41
L3MBTL1 Q9Y468 5/20 0.41
CCR1 P32246 1/20 0.41
CCR8 P51685 1/20 0.41
KDM4E B2RXH2 4/20 0.41
SLC40A1 Q9NP59 2/20 0.41
ALDH1A1 P00352 7/20 0.38
ALOX12 P18054 5/20 0.38
LMNA P02545 4/20 0.38
MAPT P10636 4/20 0.38
HTT P42858 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPSR1 Q6W5P4 3/20 0.38
CCR6 P51684 1/20 0.38
HSP90AA1 P07900 5/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
CYP3A4 P08684 3/20 0.37
TP53 P04637 2/20 0.37
ALOX15 P16050 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455362 0.87 L3MBTL1 (0.53) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL13625137 0.83 L3MBTL1 (0.44) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL13625111 0.82 KDM4E (0.44) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL13625120 0.81 NPC1 (0.45) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL4457946 0.81 L3MBTL1 (0.47) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL4044274 0.80 L3MBTL1 (0.43) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL13625126 0.80 HSD11B1 (0.45) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL8344452 0.78 KDM4E (0.56) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL16407673 0.76 COMT (0.45) HIF1AL3MBTL1CCR1CCR8KDM4E
SCHEMBL13625117 0.75 L3MBTL1 (0.43) HIF1AL3MBTL1CCR1CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-8975278-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-03-10 US disclosed
US-8975278-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-03-10 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN HIF1A 1928/4885L3MBTL1 3725/4885CCR1 3231/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN HIF1A 1928/4885L3MBTL1 3725/4885CCR1 3231/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT HIF1A 2572/4885L3MBTL1 1268/4885CCR1 4654/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN HIF1A 1928/4885L3MBTL1 3725/4885CCR1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.